Apex Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Apex Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$745K	Buy	13,918 +4,796	+53%	+$281K	0.02%	210
2015 Q4	$599K	Hold	9,122	–	–	0.01%	206
2015 Q3	$515K	Sell	9,122 -160	-2%	-$10.4K	0.01%	214
2015 Q2	$549K	Sell	9,282 -27	-0.3%	-$1.67K	0.01%	219
2015 Q1	$580K	Buy	9,309 +544	+6%	+$31.6K	0.01%	211
2014 Q4	$504K	Sell	8,765 -3,845	-30%	-$214K	0.01%	217
2014 Q3	$678K	Buy	12,610 +160	+1%	+$8.48K	0.02%	192
2014 Q2	$653K	Buy	12,450 +1,350	+12%	+$69K	0.02%	199
2014 Q1	$587K	Hold	11,100	–	–	0.02%	202
2013 Q4	$445K	Buy	11,100 +5,400	+95%	+$213K	0.02%	210
2013 Q3	$215K	Buy	+5,700	New	+$222K	0.01%	224

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Apex Capital Management's TEVA Position: Q1 2016 in Review

Apex Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 53% in Q1 2016, buying an estimated $281K and bringing the position to 13,918 shares worth $745K. The position accounts for 0.02% of the portfolio, ranked #210.

Apex Capital Management first reported a position in TEVA in Q3 2013 and has held it in 11 quarters since. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Apex Capital Management held 13,918 shares of Teva Pharmaceuticals worth $745K as of Q1 2016.
Apex Capital Management bought 4,796 Teva Pharmaceuticals shares in Q1 2016, an estimated $281K.
Teva Pharmaceuticals made up 0.02% of Apex Capital Management's portfolio in Q1 2016, its #210 holding.
Apex Capital Management first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.